In this issue of JAMA, Jones et al1 report the results of a randomized, noninferiority trial comparing 2 strategies for guiding the use of inotropes and red blood cell transfusions during early goal-directed therapy for patients with severe sepsis or septic shock. Early goal-directed therapy is a multifaceted strategy for titrating intravenous fluids, pressors, inotropes (ie, dobutamine), and transfusions to rapidly correct the physiological derangements associated with severe sepsis. In a single-center randomized trial, the use of early goal-directed therapy was associated with a decrease in mortality from 46.5% to 30.5%.2 Early goal-directed therapy is a key element of the treatment bundle suggested by the Surviving Sepsis Campaign, is widely believed to be effective, and has been implemented to varying degrees in emergency departments across the country.3- 6 However, the validity of the initial trial has been questioned by some, and the benefits of early goal-directed therapy and its components are currently being reevaluated in a number of large prospective clinical trials.7
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.